Phase 1/2 clinical trial data readouts for ALLO-501A (large B-cell lymphoma) and ALLO-316 (renal cell carcinoma) - objective response rates, duration of response, and safety profile versus autologous CAR Ts
FDA regulatory interactions including IND clearances for new programs, clinical hold resolutions, and BLA submission timelines
Cash runway updates and financing events (equity raises, debt facilities, strategic partnerships) given $200M+ annual burn rate
Competitive developments in allogeneic CAR T space from Caribou Biosciences, Precision BioSciences, and Cellectis
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, severe recessions could impact ability to raise capital at favorable valuations and affect hospital budgets for expensive cell therapies post-approval. Patient access to $200K+ cancer treatments may face reimbursement pressure during economic downturns.
High sensitivity through valuation multiple compression. As a pre-revenue biotech with negative cash flows, Allogene is valued on discounted future cash flows 5-10 years out. Rising rates (10-year Treasury) significantly reduce NPV of distant approvals and peak sales projections. Higher rates also increase cost of capital for future financing rounds and make risk-free alternatives more attractive to growth investors. The 96% six-month return likely reflects rate cut expectations improving biotech valuations.
Allogeneic CAR T technology may fail to demonstrate non-inferior efficacy to autologous products in pivotal trials, undermining entire investment thesis and $2B+ cumulative R&D spend
FDA regulatory pathway uncertainty for off-the-shelf cell therapies including potential requirements for larger safety databases or longer follow-up periods than autologous competitors
Manufacturing complexity and quality control challenges scaling allogeneic CAR T production to commercial volumes while maintaining <$100K COGS target
growth/speculative - Attracts biotech-focused growth investors and hedge funds making binary bets on clinical trial outcomes. High-risk/high-reward profile appeals to investors with 3-5 year time horizons willing to accept total loss risk for potential 5-10x returns if allogeneic CAR T platform validates. Recent 96% six-month rally suggests momentum traders and rate-cut beneficiaries entering positions. Not suitable for value or income investors given negative earnings, zero dividend, and uncertain path to profitability.
No analyst coverage available for this stock.
Trend
+7.1% vs SMA 50 · +50.0% vs SMA 200
Momentum
Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ALLO News
Unable to load news
About
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of 'off-the-shelf' CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
ALLO◀ | $2.21 | +0.94% | $524M | — | -10000.0% | — | 1500 |
| $68.91 | -3.59% | $13.3B | — | +12626.1% | -14525.8% | 1500 | |
| $520.84 | -0.71% | $11.8B | — | +43205.3% | -3008.0% | 1500 | |
| $88.52 | +0.60% | $11.5B | — | +3288.2% | -4239.0% | 1500 | |
| $181.75 | -1.59% | $10.7B | 29.2 | +1871.5% | 680.1% | 1500 | |
| $228.45 | -0.59% | $10.6B | — | +6554.5% | -2868.8% | 1500 | |
| $75.32 | +1.81% | $10.5B | 51.8 | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -0.45% | — | 40.5 | +340480.1% | -3996.9% | 1500 |